Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FDL24
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $75,716
Award facts
- Contract value 100% obligated
- $75,716.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $75,716.00 by the Defense Logistics Agency (DLA) on August 20, 2025. The delivery order, which carries no set-aside designation, is for NUCALA 100 mg/ml syringes and is scheduled for completion by August 21, 2025. This award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at approximately $500 million through November 2026, which authorizes the agency to issue firm fixed-price delivery orders for pharmaceutical products supporting Department of Defense medical supply needs.
NUCALA (mepolizumab) is a prescription biologic medication used to treat severe eosinophilic asthma and other eosinophil-mediated conditions. Through its IDC with DLA, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables to military health facilities worldwide. The company's established position as a federal pharmaceutical supplier is demonstrated by its consistent procurement success and SAM.gov registration since 2001, enabling it to serve as a critical distribution partner within the federal pharmaceutical supply chain for Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DB25FDL24?
SPE2DB25FDL24 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 20, 2025.
How much is contract SPE2DB25FDL24 worth?
The government has obligated $75,716 on SPE2DB25FDL24.
Is contract SPE2DB25FDL24 an order under another contract?
Yes. SPE2DB25FDL24 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDL24 competed?
The extent of competition for SPE2DB25FDL24 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award